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ESCAbstract Pulmonary embolism severity index (PESI) as an example of clinical model which was
designed in 2005, which comprises 11 routinely available clinical predictor variables with different
prognostic weights. On the basis of PESI score, each patient is classiﬁed into one of ﬁve classes
(I–V), with a 30 day mortality ranging from 1.1% to 24.5%. Patients in risk classes I and II are
categorized as low risk and those in risk classes III–V are categorized as high risk. The European
society of cardiology (ESC) guidelines have suggested a prognostic model that integrates clinical
and laboratory tests which categorize patients, according to individual estimates of pulmonary
embolism-related early mortality risk, into high-risk patients (early mortality risk higher than
15%), and non-high-risk patients. However, no study has so far prospectively validated this inte-
grated prognostic model in actual practice. Moreover, the results of most studies supporting the
use of biomarkers and echocardiography have not generally been adjusted to established clinical
signs of poor outcome. So the aim of this work is to compare the accuracy of PESI and ESC prog-
nostic models in risk stratiﬁcation of APE patients and their predictive role for short term progno-
sis, hoping for better risk stratiﬁcation and therapeutic decision making to improve the outcome of
APE.
Patients and methods: Forty patients who were conﬁrmed as having APE and met the inclusion
criteria were enrolled into this study. They were diagnosed as having acute pulmonary embolism
through: (1) thorough medical history, (2) clinical examination, (3) radiological evaluation [plain
X-ray and computed tomography pulmonary angiography], (4) arterial blood gases, (5) serum level
of D-dimer, (6) routine laboratory investigations and (7) electrocardiogram. All studied patients
were subjected to the following: (1) assessment of right ventricular dysfunction by: (a) echocardio-
graphy, (b) cardiac biomarkers assessment (serum levels of brain natriuretic peptide and troponin I
and 2) Prognostic risk stratiﬁcation of the patients by PESI and ESC models, then assess the
patients outcome.
Results: This study showed thirty-day outcome of APE in the form of survival was reported in
90% and adverse events in 20% of the studied patients where mortality (primary outcome) and
complications other than mortality (secondary outcome) had an equal rate (10% each).
The percentage of patients in low risk groups was nearly the same in PESI and ESC models. The
772 Abd-ElRahim Ibrahim Youssef et al.patients in intermediate class in PESI model was lower than those in ESC model. Conversely the
percentage of patients in high risk class in PESI was higher than that in ESC model. This study
showed that mortality and complications were increased with increased risk classes in both PESI
and ESC models. The highest mortality rate was reported in the high risk class which was statisti-
cally signiﬁcant in both models. Mortality prediction of APE patients in this work is statistically
highly signiﬁcant and more accurate among the high risk class in ESC model than in PESI model
with 100% speciﬁcity and PPV. At cut-off level 100 pg/ml of serum BNP, there were high sensitivity
and NPV (100% each) and the highest speciﬁcity (91.7%) in predicting the 30-day mortality among
APE patients with statistically high signiﬁcance, in comparison to serum D-dimer and troponin I.
Conclusion: (1) There is an agreement to great extent in risk stratiﬁcation of APE patients by
PESI and ESC prognostic models, where mortality rate is increased among high risk classes of both
models, (2) ESC prognostic model is more accurate than PESI model in mortality prediction of
APE patients especially in the high risk class, (3) echocardiographic evidence of RVD and elevated
plasma BNP can help to identify APE patients at increased risk of adverse short-term outcome and
(4) integration of RVD assessment by echocardiography and BNP to clinical ﬁndings improves the
prognostic value of ESC model.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Risk evaluation and prognostic stratiﬁcation are the corner
stones of modern acute pulmonary embolism (APE) manage-
ment. Prognostic stratiﬁcation to identify high risk patients
needing to receive more aggressive pharmacological and closer
monitoring is of utmost importance [1]. Pulmonary embolism
severity index (PESI) as an example of clinical model which
was designed in 2005, comprises 11 routinely available clinical
predictor variables with different prognostic weights. On the
basis of PESI score, each patient is classiﬁed into one of ﬁve
classes (I–V), with a 30 day mortality ranging from 1.1% to
24.5% [2]. The European society of cardiology (ESC) guideli-
nes have suggested a prognostic model that integrates clinical
and laboratory tests which categorize patients, according to
individual estimates of PE-related early mortality risk, into
high-risk patients (early mortality risk higher than 15%), and
non-high-risk patients [3]. However, no study has so far
prospectively validated this integrated prognostic model in
actual practice. Moreover, the results of most studies support-
ing the use of biomarkers and echocardiography have not gen-
erally been adjusted to established clinical signs of poor
outcome [4]. So the aim of this work is to compare the accu-
racy of PESI and ESC prognostic models in risk stratiﬁcation
of APE patients and their predictive role for short term prog-
nosis, hoping for better risk stratiﬁcation and therapeutic deci-
sion making to improve the outcome of APE.
Patients and methods
This prospective operational study was carried out in Chest
Department Zagazig University Hospitals in the period from
March 2013 to January 2015.
Patients
Forty patients who were conﬁrmed as having APE and met the
inclusion criteria were enrolled to the study. They were 17males and 23 females with a mean age of 52.77 ± 11.74.
Informed consent was taken from all participants of the study.
Inclusion criteria
– Patients who are P18 years of age [5].
– Patients must fulﬁll criteria for diagnosis of APE [6]: (a)
High clinical probability of PE, or low/intermediate clinical
probability with a positive D-dimer test (P500 ng/mL) as
documented by Well’s criteria.
– Positive ﬁndings of PE by computed tomography pul-
monary angiography (CTPA) [7].
Exclusion criteria
– Patients on curative anticoagulant treatment for more than
24 h or unavailable for follow up were excluded from the
study [5].
Diagnosis of APE
Was achieved for all patients upon inclusion to the study as
follows:
(1) Thorough medical history was recorded on admission
including information about presentation symptoms,
comorbidities and risk factors for thromboembolic
events (such as age, gender, immobilization in the pre-
ceding three months, hormone replacement or hormonal
contraception therapy, family history of venous throm-
boembolism, active cancer, varicose veins, smoking
and overweight) [6].
(2) Clinical examination.– General examination.
– Assessment of heart rate, respiratory rate, body
temperature, blood pressure and presence of
delirium.
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following criteria; systolic blood pressure <90 -
mmHg, or a drop of systolic blood pressure by
P40 mmHg forP15 min, with signs of end-organ
hypoperfusion; or need for catecholamine admi-
nistration to maintain adequate organ perfusion
and a systolic blood pressure P90 mmHg) [8].Predictors  Score    
Age  Years Low risk  
(≤ 65 class I, 66-85, class II) 
Mortality 1.9% 
Male sex  + 10  
Cancer  + 30  
Heart failure  + 10   
COPD + 10  Intermediate risk 
86-105 class III, 106-125 class IV) 
Mortality 18.4% 
HR ≥ 110 b.p.m + 20  
SBP <100 mmHg + 30  
RR > 30 breath per 
minute 
+ 20   
BT < 36 ° C + 20  High risk  
(> 125 class V) 
Mortality 25% 
Delirium  + 60  
SaO2 < 90% + 20  
 Total – Local examination (chest examination).
(3) Radiological evaluation: Plain X-ray and CTPA were
done for all studied patients.
(4) Arterial blood gases: Analysis by means of a blood gas
analyzer; (RapidlabTM 348 Bayer Health Care).
(5) Serum level of D-dimer: The D-dimer cut off value
P500 ng/ml is considered positive and results of
<500 ng/ml is considered negative [9].
(6) Routine laboratory investigations: kidney function tests,
liver function tests, complete blood picture and coagula-
tion proﬁle.
(7) Electrocardiogram (ECG).
Management strategies
Besides hemodynamic and respiratory support, intravenous
unfractionated heparin at standard doses or weight-based
doses of subcutaneous low molecular weight heparins were
administered as soon as PE was suspected. Thrombolysis
was administered in patients with shock/hypotension unless a
contraindication was present. Oral vitamin K antagonist ther-
apy was started on day 1 or day 2 of heparin treatment contin-
ued, with an International Normalized Ratio of 2.5 [10].
Methods
Assessment of right ventricular dysfunction
Echocardiography. For assessment of right ventricular dys-
function (RVD) within 24 h of APE diagnosis. RVD was
assessed by standard color two-dimensional echocardiographic
doppler examinations (GE vivid E9 5s probe).
Diagnostic Criteria of right ventricular dysfunction (RVD)
[11]:
 Right ventricular dilatation (end-diastolic diameter
>32 mm or right/left ventricular end-diastolic diameter
ratio >1 in an apical four-chamber view).
 Hypokinesia of RV.
 Abnormal motion of the interventricular septum.
 Right ventricular systolic pressure (RVSP) >30 mmHg,
normally RVSP = 20–30 mmHg.
Cardiac biomarkers: after diagnosis of APE was established
blood samples were collected for assessment of cardiac
biomarkers.
 Serum level of brain natriuretic peptide (BNP):
Blood samples were collected and centrifuged. The resulting
plasma was frozen and stored at 20 C. At the end of the
study, circulating levels of BNP were determined on CON-
VRGY EL-READER 96X using ELISA technique by investi-gators blind to patients baseline characteristics and clinical
outcome [5]. The BNP value in normal healthy adults reported
by central laboratory at Zagazig University Hospitals is 30–
40 pg/ml.
 Serum level of Troponin-I:
Blood samples were collected and centrifuged and the
plasma level of troponin-I was determined on MINIVIDAS
(SN IVD, 1202911) using enzyme linked ﬂuorescent assay
(ELFA) [5]. The value in normal healthy adults reported by
central laboratory at Zagazig University Hospitals is
<0.01 ug/L.
Prognostic risk stratification models:
 Original PESI prognostic model [1]: Each patient’s baseline
characteristics determined their risk classiﬁcation according
to the criteria for the predictive PESI model, Fig. 1.
A total point score for a given patient is obtained by sum-
ming the patient’s age in years and the points for each applica-
ble predictor. Assignments of patients corresponded to the
reported risk classes [10].
– Outcome [10]:
Short-term (30 days) outcome was assessed in the form of:
 Primary outcome which included death (all causes) and,
 Secondary outcome which included any of the following;
delayed hemodynamic stability or recurrent PE or non-
fatal bleeding.
Statistical analysis
All data were analyzed using SPSS 15.0 for windows (SPSS
Inc., Chicago, IL, USA) & MedCalc 13 for windows (MedCalc
Software bvba). Continuous data were expressed as the mean
± SD, and the categorical data are expressed as a number
(percentage). Receiver Operating Characteristic (ROC) curve
was obtained to calculate the cut-off point for BNP, troponin
I and D-dimer. The sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV), which
describe probability of PESI, ESC models, BNP, troponin IFigure 1 PESI prognostic model.
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of APE were calculated. P< 0.05 was considered statistically
signiﬁcant (see Figs. 2–4).
Results
Table 1 showed that thirty-day outcome of APE in the studied
patients in the form of survival was reported in 36/40 (90%)
and adverse events in 8/40 (20%) where mortality (primary
outcome) and complications other than mortality (secondary
outcome) had equal rate 4/40 (10%) each.
Table 2 showed the percentage of patients in low risk
groups was nearly the same in PESI and ESC models
(32.5% & 35%, respectively). The percentage of patients in
intermediate class in PESI model was lower than those in
ESC model (50% vs 60%, respectively). Conversely, the per-
centage of patients in high risk class in PESI was higher than
that in ESC model (17% vs 5%, respectively). Agreement of
the rating of the two models among APE patients as regards
the low, intermediate and high risk classes (13, 20 & 2 cases,
respectively) was considered excellent (kappa = 0.74)
(P< 0.001).
This study showed that 30-days primary outcome (mortal-
ity) and secondary outcome (complications, not tabulated)
were increased with increased risk classes in both PESI and
ESC models. The highest mortality rate was reported in the
high risk class which was statistically signiﬁcant in PESI model
(3/7 patients, 42.9%) (P< 0.05) and statistically highly signif-
icant in ESC model (2/2 patients, 100%) (P< 0.001) (Tables 3
and 4), where secondary outcome (complications) within PESI
model only shows signiﬁcant predominance in the high risk
class (3/7 patients, 42.9%), (P< 0.05). But the proportion of
complication that was reported in intermediate class in ESC
model (4/24 patients, 16.7%) was statistically non-signiﬁcant
(P> 0.05).
Mortality prediction of APE patients in this work is statis-
tically highly signiﬁcant more accurate among high risk class in
ESC model (j value = 0.643) (P< 0.001) than in PESI model
(j value = 0.479) (P< 0.05) with 100% speciﬁcity and PPV.Figure 2 ESC progAlso in this study, on comparing the higher-risk classes
(intermediate-risk plus high-risk classes) to low-risk, it was
found that both models showed a high sensitivity (100% each),
low PPV about 15% (14.8%, 15.45%, respectively) and high
NPV (100% each) in predicting the 30-day mortality with
kappa value being higher in ESC model (0.113) vs (0.102) in
PESI model but with no statistical signiﬁcance (P> 0.05)
(Tables 5 and 6).
In this study, cut-off serum level 100 pg/ml of BNP had
high sensitivity and NPV (100% each) and the highest speci-
ﬁcity (91.7%) in predicting the 30-day mortality among APE
patients with statistically high signiﬁcance (P< 0.001), in
comparison to serum D-dimer cut-off level of 3192 (ng/ml)
and serum troponin I cut-off level of 0.05 (ug/L) which showed
no signiﬁcance statistically (P> 0.05) in predicting the 30-day
mortality among studied patients (Table 7).
Also cut-off serum level 85 pg/ml of BNP had high sensitiv-
ity and NPV (100% each) with good speciﬁcity (88.9%) in pre-
dicting 30-day complications among the studied patients with
statistically high signiﬁcance (P< 0.01) (Table 8).
Discussion
Acute PE has a broad spectrum of clinical manifestations,
ranging from patients who die of sudden cardiac death to
patients who are literally asymptomatic. The mortality attribu-
table to PE approximates 50% in patients who are hypotensive
at the time of admission (high risk) and current guidelines rec-
ommend using thrombolytics in these patients. About 90% of
all acute PE patients are normotensive at the time of admis-
sion, but carry very heterogenous short-term mortality, rang-
ing from <1% to about 15% [12]. Concurrently with the
diagnosis of PE, prognostic assessment is required for risk
stratiﬁcation and therapeutic decision-making [10]. As several
PE prognostic models are available but have limitations in
daily clinical practice, a few have been recommended for risk
stratiﬁcation in acute PE [13]. Although some studies have
investigated the potential usefulness of humoral data addition
to the PESI model, few studies have directly compared thenostic model [1].
Figure 3 ROC curve of D-dimer, BNP and troponin I as predictors of the 30-day mortality (primary outcome) among the studied APE
patients.
Figure 4 ROC curve of D-dimer, BNP and troponin I as predictors of 30-day complications (secondary outcome) among the studied
APE patients.
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PESI model [14]. So the aim of this work is to compare the
accuracy of PESI and ESC prognostic models in risk stratiﬁca-
tion of APE patients and their predictive role for short term
prognosis.
Thirty-day outcome of APE in the current study patients in
the form of survival was reported in 36/40 (90%) and adverse
events in 8/40 (20%) where mortality (primary outcome) and
complications other than mortality (secondary outcome) had
equal rate 4/40 (10% each) (Table 1).
This result is in agreement with that of Jime´nez et al. [15],
Vanni et al. [10] and Ferrer et al. [16] who reported a 30-dayTable 1 Thirty-day outcome of the studied patients with
acute pulmonary embolism (APE).
Outcome of APE (n= 40) No %
Primary Survival 36 90
Death 4 10
Secondary Absence of Complications 36 90
Presence of complications 4 10
Table 2 Risk stratiﬁcation of acute pulmonary embolism
(APE) patients according to the studied prognostic PESI and
ESC models.
APE (n= 40) kappa
value
P-value
PESI
model
ESC
model
No % No %
Low risk class 13 32.5 14 35 0.74 0.000
(<0.001)Intermediate risk
class
20 50 24 60
High risk class 7 17.5 2 5
Table 3 Frequency of the 30-day mortality (primary outcome) amo
Mortality No (%)
Survive Death
Low risk 13 (100%) 0 (0%)
Intermediate risk 19 (95%) 1 (5%)
High risk 4 (57.1%) 3 (42.9%)
Total 36 (90%) 4 (10%)
Table 4 Frequency of the 30-day mortality (primary outcome) amo
Primary outcome (Mortality)
Survive Death
Low risk 14 (100%) 0 (0%)
Intermediate risk 22 (91.7%) 2 (8.3%)
High risk 0 (0%) 2 (100%)
Total 36 (90%) 4 (10%)mortality rate of PE patients equal to 10%, 8% and 9.5%,
respectively.
On the other hand, the 30-day mortality rate in our study is
higher than results of Sanchez et al. [17] who found that the 30-
day mortality of APE patients was 2.8% and this is attributed
to the fact that their study was done on hemodynamically
stable patients only. Also this study’s 30-day mortality rate is
lower than that of Soares et al. [18] who found that the 30-
day mortality rate of APE patients was 20%. This higher mor-
tality may be attributed to longer period of follow up (90 days)
and larger number of studied patients in their work.
Also this work result is in agreement with that of Sanchez
et al. [5] and Jime´nez et al. [15] who reported 30-day complica-
tions of PE patients equal to 7.4%, 10%, respectively.
On the other hand, this work’s 30-day complication is
higher than results of Lankeit et al. [13] who found that the
30-day complication of APE patients was 4% and Sanchez
et al. [17] who found that the 30-day complication of APE
patients was 5.6% and this is attributed to the fact that their
study was done on hemodynamically stable patients only.
After diagnosis, the risk stratiﬁcation of patients with PE is
extremely important for management and decision making
regarding therapy [19].
Risk stratiﬁcation of patients with PE may enable deﬁnition
of a low-risk group that may be treated on an outpatient basis
and a high-risk group that should be admitted to hospital for
close medical supervision [3].
In this study, percentage of patients in low risk groups is
nearly the same in PESI and ESC models (32.5% & 35%,
respectively). The patients in intermediate class in PESI model
was lower than those in ESC model (50% vs 60%, respec-
tively). Conversely percentage of patients in high risk class in
PESI was higher than that in ESC model (17% vs 5%, respec-
tively). Agreement of the rating of the two models among APE
patients as regards the low, intermediate and high classes (13,
20 & 2 cases, respectively) was considered excellent
(kappa = 0.74) (Table 2).
This result is in agreement with that of Vanni et al. [10] who
found the proportion of patients assigned by PESI model vsng APE patients according to risk stratiﬁcation by PESI model.
Total X2 P-value
13 (100%) 10.397 0.006 < 0.05
20 (100%)
7 (100%)
40 (100%)
ng APE patients according to risk stratiﬁcation by ESC model.
Total X2 P-value
14 (100%) 19.63 0.000 < 0.001
24 (100%)
2 (100%)
40 (100%)
Table 5 Test characteristics PESI model for predicting mortality (primary outcome) of APE patients.
Mortality Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
kappa
value
P value
Death
N= 4
Survival
N = 36
High + intermediate risk classes
vs low risk class (total n= 40)
High + intermediate
risk classes n= 27
4 23 100 36 14.8 100 0.102 0.144
Low risk class
n= 13
0 13
High risk class vs low
+ intermediate risk classes (total
n= 40)
High risk class n= 7 3 4 75 88.9 42.9 97 0.479 0.001
(<0.01)
Table 6 Test characteristics of ESC model for predicting mortality (primary outcome) of APE patients.
Mortality Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
kappa
value
P-value
Death
N= 4
Survival
N = 36
High + intermediate risk
classes vs low risk (total n= 40)
High
+ intermediate risk
classes n= 26
4 22 100 38.9 15.4 100 0.113 0.122
Low risk n= 14 0 24
High risk class vs Low
+ intermediate risk classes
(total n= 40)
High risk class
n= 2
2 0 50 100 100 94.7 0.643 0.000
(<0.001)
Low
+ intermediate risk
classes n= 38
2 36
Table 7 Test characteristics of cut-off levels of serum BNP, D-dimer, troponin I for predicting the 30-day mortality (primary
outcome) among the studied APE patients.
Cut-oﬀ level Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) kappa P-value
BNP = 100 (pg/ml) 100 91.7 57 100 0.688 0.000 (<0.001)
D-dimer = 3192 (ng/ml) 75 61 17.5 95.7 0.148 0.17
Troponin I = 0.05 (ug/L) 75 63.9 18.8 95.8 0.167 0.13
Table 8 Test characteristics of cut-off serum levels of BNP, D-dimer, troponin I for predicting 30-day complications (secondary
outcome) among the studied APE patients.
Cut-oﬀ level Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Kappa P-value
BNP = 85 (pg/ml) 100 88.9 50 100 0.62 0.001 (<0.01)
D-dimer = 2500 (ng/ml) 50 44.4 9 88.9 0.02 0.83
Troponin I = 0.05 (ug/L) 75 63.9 18.8 95.8 0.167 0.13
Comparison of two prognostic models 777ESC model in different risk classes as follows respectively; low
risk class (31% vs 40%), intermediate risk class (49% vs 54%)
and high risk class (20% vs 6%).
Also other studies which compare low risk vs high risk
classes only are in agreement with this work in the proportions
of low risk classes of PESI and ESC models which were 31%
vs 39% and the high risk class reported a higher proportion
than this work (69% vs 61%) [13]. In Kilic et al. [19] study,
proportions for low risk class were 38% vs 42% and for high
risk class were 62% vs 58%. The higher proportion reportedfor high risk classes in those studies was due to the fact that
intermediate class was merged with high class.
This study showed that, the 30-day primary outcome (mor-
tality) and secondary outcome (complications) were increased
with increased risk classes of both PESI and ESC models. The
highest mortality rate was reported in the high risk class which
was signiﬁcant for PESI model (3/7 patients, 42.9%) and ESC
model (2/2 patients, 100%) (Tables 3 and 4), where the sec-
ondary outcome (complications) within PESI model only
shows signiﬁcant predominance in the high risk class (3/7
778 Abd-ElRahim Ibrahim Youssef et al.patients, 42.9%). But the proportion of complication that was
reported in intermediate class of ESC model (4/24 patients,
16.7%) was statistically non-signiﬁcant.
These results are in agreement with those of Vanni et al. [10]
who reported that mortality is signiﬁcantly increased through
the risk classes in both prognostic models (mortality was
20% in high risk, 6% in intermediate risk and 3% in low risk
of PESI model and mortality was 30% in high risk, 9% in
intermediate risk and 2% in low risk in ESC model and sec-
ondary outcome in the three classes of PESI model were 2%,
7% and 15%, respectively and in the three classes in ESC
model were 3%, 7% and 22%, respectively) and Kilic et al.
[19] who found no deaths among low risk patients classiﬁed
by the sPESI, while Patients classiﬁed as high-risk using the
sPESI mortality was 15.9%.
Overall agreement of rating deaths according to PESI and
ESC models is signiﬁcantly higher in ESC model
(kappa = 0.643) than PESI model (kappa = 0.479) with
100% speciﬁcity and PPV (Tables 5 and 6). This indicated that
the ESC model had higher accuracy in identifying high-risk
patients.
Also in this study, mortality prediction assessed by compar-
ing the higher-risk classes (intermediate-risk plus high-risk
classes) to low-risk, it was found that both models showed a
high sensitivity (100%) each, low PPV about 15% (14.8%,
15.45%, respectively) and high NPV (100%) each, for predict-
ing the 30-day mortality with kappa value being higher for
ESC model (0.113) vs (0.102) in PESI model but with no sta-
tistical signiﬁcance (Tables 5 and 6), while, when high-risk
class was compared with the lower-risk classes (intermediate
and low risk), the ESC model showed lower sensitivity (50%
vs 75% in PESI), but higher speciﬁcity (100% vs 88.9% in
PESI) and higher PPV (100% vs 42.5% in PESI) with a ﬁnal
kappa value (0.643) which was higher than that of the PESI
model (0.479) in predicting the 30-day mortality (Tables 5
and 6). This is in agreement with ESC, [3] and Vanni et al. [10].
Lankeit et al. [13] and Kilic et al. [19] studies assessed the
value of mortality prediction with sPESI and ESC models as
a whole score, without speciﬁcation to risk classes, concluded
that sPESI had a higher sensitivity and a higher NPV, than
the ESC model for predicting in-hospital adverse events
including mortality. Subsequently, sPESI appeared to be more
accurate than the ESC model in excluding short-term adverse
events, including in-hospital overall mortality.
Finally, on assessing evidence of RVD contribution to
short term outcome explaining its role in improving prediction
role of ESC model, the current work reported that, 30-day
adverse events was signiﬁcantly associated with RVD echocar-
diographic diagnostic criteria; increased RV diameter
>32 mm, RVSP >30 mmHg and increased RV diameter/LV
diameter ratio. Also high levels of plasma BNP (pg/ml) is con-
sidered as a risk factor of 30-day adverse events among studied
patients with a statistically high signiﬁcance, (These results
were not tabulated).
In this study, a cut-off serum level 100 pg/ml of BNP had
high sensitivity and NPV (100% each) and the highest speci-
ﬁcity (91.7%) in predicting the 30-day mortality among APE
patients with a statistically high signiﬁcance, in comparison
to serum D-dimer cut-off level of 3192 (ng/ml) and serum tro-
ponin I cut-off level of 0.05 (ug/L) which had no statistical sig-
niﬁcance (Table 7).Also a cut-off serum level of 85 pg/ml of BNP had high sen-
sitivity, and NPV (100% each) with good speciﬁcity (88.9%)
for predicting 30-day complications among the studied
patients with a statistically high signiﬁcance (Table 8).
This result is in agreement with that of Cavallazzi et al. [20]
and Coutance et al. [21] who found in their meta-analysis that
elevated BNP or NT-proBNP levels can help to identify
patients with acute PE at high risk of short-term death and
adverse outcome events. However, while sensitivity (93%) of
this biomarker is high to detect patients at risk of death or
of serious adverse events, the speciﬁcity (48%) remains low.
In keeping with these results, however, the high negative pre-
dictive value (99%) might be useful for clinicians to select
patients with a likely uneventful follow-up.
It was obvious that, BNP and echocardiography may be
useful determinants of the short-term outcome for patients
with PE, together with clinical ﬁndings. Patients with PE can
be stratiﬁed according to the initial risk of adverse outcome,
using a simple score based on clinical, echocardiographic,
and biochemical variables.
Conclusions
From this study, it can be concluded that: (1) There is an
agreement to great extent in risk stratiﬁcation of APE patients
by PESI and ESC prognostic models, where mortality rate is
increased among high risk classes of both models. (2) ESC
prognostic model is more accurate than PESI model in mortal-
ity prediction of APE patients especially in the high risk class.
(3) Echocardiographic evidence of RVD and elevated plasma
BNP can help to identify APE patients with an increased risk
of adverse short-term outcome. (4) Integration of RVD assess-
ment by echocardiography and BNP to clinical ﬁndings
improves the prognostic value of ESC model.
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